RECOMBINANT-HUMAN-ERYTHROPOIETIN TREATMENT OF POSTPARTUM ANEMIA - PRELIMINARY-RESULTS

Citation
G. Makrydimas et al., RECOMBINANT-HUMAN-ERYTHROPOIETIN TREATMENT OF POSTPARTUM ANEMIA - PRELIMINARY-RESULTS, European journal of obstetrics, gynecology, and reproductive biology, 81(1), 1998, pp. 27-31
Citations number
14
Categorie Soggetti
Reproductive Biology","Obsetric & Gynecology
ISSN journal
03012115
Volume
81
Issue
1
Year of publication
1998
Pages
27 - 31
Database
ISI
SICI code
0301-2115(1998)81:1<27:RTOPA->2.0.ZU;2-3
Abstract
Objectives: The aim of this study was to investigate the efficacy of r ecombinant human erythropoietin (rHuEpo) in postpartum anemia. Study d esign: At the University Hospital of Ioannina, rHuEpo was administrate d subcutaneously to twenty anemic women (hemoglobin [Hb]<10 g/dl), for 15 days following delivery; all were given iron and folic acid per os . Twenty other women (the control group) with postpartum anemia (Hb<10 g/dl), received only iron and folic acid. The Mann-Whitney U-test was used for the comparison of hematological indices between the two grou ps, on days 1, 3, 5, 10, 15 and 40 postdelivery. Results: On day 3, re ticulocyte counts were significantly higher in the women who received rHuEpo, as compared to the controls (P<0.05). The mean Hb value increa sed to >2 g/dl in the group undergoing rHuEpo therapy as compared to 0 .7 g/dl in the control group on day 5 (P<0.05). Furthermore, two women in the control group required blood transfusions, while no transfusio ns were required by the rHuEpo group. Conclusions: rHuEpo administrati on is useful for a more rapid amelioration of hematological indices in women with postpartum anemia. Further, the dose given in this study w as not associated with significant side-effects. (C) 1998 Elsevier Sci ence Ireland Ltd. All rights reserved.